Veronica Conca, Roberto Moretto, Sara Lonardi, Carlotta Antoniotti, Filippo Pietrantonio, Federica Marmorino, Lorenzo Antonuzzo, Beatrice Borelli, Eleonora Perissinotto, Giovanni Randon, Marco Maria Germani, Ilaria Toma, Francesco Sullo, Gianluca Masi, Carmelo Pozzo, Cristina Morelli, Angela Buonadonna, Luca Boni, Daniele Rossini, Chiara Cremolini. "Upfront modified FOLFOXIRI plus panitumumab (pan) versus FOLFOX/pan for unresectable
            <i>RAS</i>
            and
            <i>BRAF</i>
            wild-type (wt) metastatic colorectal cancer (mCRC) patients: Overall survival (OS) results from the phase III TRIPLETE study by GONO.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.3512